rbd1016
Nucleic acidexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04685564)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06649266 | Phase 2 | Aug 21, 2024 | Ribocure Pharmaceuticals AB |
| NCT05961098 | Phase 2 | Aug 21, 2023 | Suzhou Ribo Life Science Co. Ltd. |
| NCT05017116 | Phase 1 | Aug 9, 2021 | Suzhou Ribo Life Science Co. Ltd., The University of Hong Kong |
| NCT04685564 | Phase 1 | Dec 31, 2020 | Scientia Clinical Research Limited Sydney, Suzhou Ribo Life Science Co. Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Ribo Life Science Co. Ltd. | For profit | 3 | 3 | 2 | 2020 |
| Ribocure Pharmaceuticals AB | For profit | 1 | 1 | 1 | 2024 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2020 |
| The University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1